Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05716477 · ClinicalTrials.gov registry record
Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved Patients
A clinical trial, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- 146
- Enrollment target
NCT05716477: Completed study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT05716477 is a clinical trial that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 146 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05716477 has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 146 participants
- Enrollment target
Study Summary
This clinical trial evaluates the use of a blood test (Guardant Shield™) for colorectal cancer screening. Colorectal cancer is the third leading cancer and cause of death in the United States. Screening may help doctors find colorectal cancer early when it is easier to treat yet nearly a third of all people eligible for screening have never had a screening test performed. Currently, doctors use a stool- based test such as the fecal immunochemical test (FIT) and visual tests such as a colonoscopy. Blood based testing such as Guardant Shield™, may provide a quick and effective way to screen patients that are hard to reach or with limited access (underserved).
Primary Outcome
The number and percentage of patients consented out of those approached to be summarized.
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Survey Administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2022-12-23 |
| Est. Completion | 2024-11-30 |
What the finished NCT05716477 record still lists
NCT05716477 is an observational study that tracks outcomes without assigning an intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT05716477 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05716477 about?
NCT05716477 is a clinical study titled "Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved Patients". This clinical trial evaluates the use of a blood test (Guardant Shield™) for colorectal cancer screening. Colorectal cancer is the third leading cancer and cause of death in the United States. Screening may help doctors find colorectal cancer early when it is easier to treat yet nearly a third of al...
What is the current status of trial NCT05716477?
This trial is currently completed. The enrollment target is 146 participants. The study started on 2022-12-23. Estimated completion is 2024-11-30.
What interventions are being tested in trial NCT05716477?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Survey Administration (OTHER).
Who is sponsoring clinical trial NCT05716477?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI